Top

Published in:

Open Access 01-12-2013 | Review

The miRNA world of polyomaviruses

Authors: Ole Lagatie, Luc Tritsmans, Lieven J Stuyver

Published in: Virology Journal | Issue 1/2013

Abstract

Polyomaviruses are a family of non-enveloped DNA viruses infecting several species, including humans, primates, birds, rodents, bats, horse, cattle, raccoon and sea lion. They typically cause asymptomatic infection and establish latency but can be reactivated under certain conditions causing severe diseases. MicroRNAs (miRNAs) are small non-coding RNAs that play important roles in several cellular processes by binding to and inhibiting the translation of specific mRNA transcripts. In this review, we summarize the current knowledge of microRNAs involved in polyomavirus infection. We review in detail the different viral miRNAs that have been discovered and the role they play in controlling both host and viral protein expression. We also give an overview of the current understanding on how host miRNAs may function in controlling polyomavirus replication, immune evasion and pathogenesis.

Available only for authorised users

Imperiale MJ, Major EO: Polyomaviruses. Fields Virology. Edited by: Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE. 2007, Philiadelphia, PA: Lippincott Williams & Wilkins, 2263-2298. 5

Liddington RC, Yan Y, Moulai J, Sahli R, Benjamin TL, Harrison SC: Structure of simian virus 40 at 3.8-A resolution. Nature. 1991, 354 (6351): 278-284. 10.1038/354278a0.PubMed

Stehle T, Gamblin SJ, Yan Y, Harrison SC: The structure of simian virus 40 refined at 3.1 A resolution. Structure. 1996, 4 (2): 165-182. 10.1016/S0969-2126(96)00020-2.PubMed

Gjoerup O, Chang Y: Update on human polyomaviruses and cancer. Adv Cancer Res. 2010, 106: 1-51.PubMed

International Committee on Taxonomy of Viruses., Van Regenmortel MHV, International Union of Microbiological Societies, Virology Division: Virus taxonomy: classification and nomenclature of viruses: seventh report of the International Committee on Taxonomy of Viruses. 2000, San Diego: Academic Press

Stewart SE, Eddy BE, Borgese N: Neoplasms in mice inoculated with a tumor agent carried in tissue culture. J Natl Cancer Inst. 1958, 20 (6): 1223-1243.PubMed

Sweet BH, Hilleman MR: The vacuolating virus, S.V. 40. Proc Soc Exp Biol Med. 1960, 105: 420-427. 10.3181/00379727-105-26128.PubMed

Gardner SD, Field AM, Coleman DV, Hulme B: New human papovavirus (B.K.) isolated from urine after renal transplantation. Lancet. 1971, 1 (7712): 1253-1257.PubMed

Padgett BL, Walker DL, ZuRhein GM, Eckroade RJ, Dessel BH: Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet. 1971, 1 (7712): 1257-1260.PubMed

10.

DeCaprio JA, Garcea RL: A cornucopia of human polyomaviruses. Nat Rev Microbiol. 2013, 11 (4): 264-276. 10.1038/nrmicro2992.PubMedPubMedCentral

11.

Dalianis T, Hirsch HH: Human polyomaviruses in disease and cancer. Virology. 2013, 437 (2): 63-72. 10.1016/j.virol.2012.12.015.PubMed

12.

Van Ghelue M, Khan MT, Ehlers B, Moens U: Genome analysis of the new human polyomaviruses. Rev Med Virol. 2012, 22 (6): 354-377. 10.1002/rmv.1711.PubMed

13.

Korup S, Rietscher J, Calvignac-Spencer S, Trusch F, Hofmann J, Moens U, Sauer I, Voigt S, Schmuck R, Ehlers B: Identification of a novel human polyomavirus in organs of the gastrointestinal tract. PLoS One. 2013, 8 (3): e58021-10.1371/journal.pone.0058021.PubMedPubMedCentral

14.

Ferenczy MW, Marshall LJ, Nelson CD, Atwood WJ, Nath A, Khalili K, Major EO: Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev. 2012, 25 (3): 471-506. 10.1128/CMR.05031-11.PubMedPubMedCentral

15.

Tavazzi E, White MK, Khalili K: Progressive multifocal leukoencephalopathy: clinical and molecular aspects. Rev Med Virol. 2011, 22 (1): 18-32.PubMedPubMedCentral

16.

White MK, Khalili K: Pathogenesis of progressive multifocal leukoencephalopathy–revisited. J Infect Dis. 2011, 203 (5): 578-586. 10.1093/infdis/jiq097.PubMedPubMedCentral

17.

Kuypers DR: Management of polyomavirus-associated nephropathy in renal transplant recipients. Nat Rev Nephrol. 2012, 8 (7): 390-402. 10.1038/nrneph.2012.64.PubMed

18.

White MK, Gordon J, Khalili K: The rapidly expanding family of human polyomaviruses: recent developments in understanding their life cycle and role in human pathology. PLoS Pathog. 2013, 9 (3): e1003206-10.1371/journal.ppat.1003206.PubMedPubMedCentral

19.

Jiang M, Abend JR, Johnson SF, Imperiale MJ: The role of polyomaviruses in human disease. Virology. 2009, 384 (2): 266-273. 10.1016/j.virol.2008.09.027.PubMedPubMedCentral

20.

van der Meijden E, Janssens RW, Lauber C, Bouwes Bavinck JN, Gorbalenya AE, Feltkamp MC: Discovery of a new human polyomavirus associated with trichodysplasia spinulosa in an immunocompromized patient. PLoS Pathog. 2010, 6 (7): e1001024-10.1371/journal.ppat.1001024.PubMedPubMedCentral

21.

Knowles WA: Discovery and epidemiology of the human polyomaviruses BK virus (BKV) and JC virus (JCV). Adv Exp Med Biol. 2006, 577: 19-45. 10.1007/0-387-32957-9_2.PubMed

22.

Trowbridge PW, Frisque RJ: Identification of three new JC virus proteins generated by alternative splicing of the early viral mRNA. J Neurovirol. 1995, 1 (2): 195-206. 10.3109/13550289509113966.PubMed

23.

Abend JR, Joseph AE, Das D, Campbell-Cecen DB, Imperiale MJ: A truncated T antigen expressed from an alternatively spliced BK virus early mRNA. J Gen Virol. 2009, 90 (Pt 5): 1238-1245.PubMedPubMedCentral

24.

Shuda M, Feng H, Kwun HJ, Rosen ST, Gjoerup O, Moore PS, Chang Y: T antigen mutations are a human tumor-specific signature for Merkel cell polyomavirus. Proc Natl Acad Sci USA. 2008, 105 (42): 16272-16277. 10.1073/pnas.0806526105.PubMedPubMedCentral

25.

Zhuang G, Wu X, Jiang Z, Kasman I, Yao J, Guan Y, Oeh J, Modrusan Z, Bais C, Sampath D, et al: Tumour-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathway. EMBO J. 2012, 31 (17): 3513-3523. 10.1038/emboj.2012.183.PubMedPubMedCentral

26.

Lilyestrom W, Klein MG, Zhang R, Joachimiak A, Chen XS: Crystal structure of SV40 large T-antigen bound to p53: interplay between a viral oncoprotein and a cellular tumor suppressor. Genes Dev. 2006, 20 (17): 2373-2382. 10.1101/gad.1456306.PubMedPubMedCentral

27.

Sowd GA, Fanning E: A wolf in sheep's clothing: SV40 co-opts host genome maintenance proteins to replicate viral DNA. PLoS Pathog. 2012, 8 (11): e1002994-10.1371/journal.ppat.1002994.PubMedPubMedCentral

28.

Welcker M, Clurman BE: The SV40 large T antigen contains a decoy phosphodegron that mediates its interactions with Fbw7/hCdc4. J Biol Chem. 2005, 280 (9): 7654-7658.PubMed

29.

Yardimci H, Wang X, Loveland AB, Tappin I, Rudner DZ, Hurwitz J, van Oijen AM, Walter JC: Bypass of a protein barrier by a replicative DNA helicase. Nature. 2012, 492 (7428): 205-209. 10.1038/nature11730.PubMedPubMedCentral

30.

Cheng J, Rozenblatt-Rosen O, Paulson KG, Nghiem P, Decaprio JA: Merkel Cell Polyomavirus Large T Antigen has Growth Promoting and Inhibitory Activities. J Virol. 2013, 81 (11): 6118-6126.

31.

Pallas DC, Shahrik LK, Martin BL, Jaspers S, Miller TB, Brautigan DL, Roberts TM: Polyoma small and middle T antigens and SV40 small t antigen form stable complexes with protein phosphatase 2A. Cell. 1990, 60 (1): 167-176. 10.1016/0092-8674(90)90726-U.PubMed

32.

Pallas DC, Weller W, Jaspers S, Miller TB, Lane WS, Roberts TM: The third subunit of protein phosphatase 2A (PP2A), a 55-kilodalton protein which is apparently substituted for by T antigens in complexes with the 36- and 63-kilodalton PP2A subunits, bears little resemblance to T antigens. J Virol. 1992, 66 (2): 886-893.PubMedPubMedCentral

33.

Good PJ, Welch RC, Barkan A, Somasekhar MB, Mertz JE: Both VP2 and VP3 are synthesized from each of the alternative spliced late 19S RNA species of simian virus 40. J Virol. 1988, 62 (3): 944-953.PubMedPubMedCentral

34.

Good PJ, Welch RC, Ryu WS, Mertz JE: The late spliced 19S and 16S RNAs of simian virus 40 can be synthesized from a common pool of transcripts. J Virol. 1988, 62 (2): 563-571.PubMedPubMedCentral

35.

Grass DS, Manley JL: Selective translation initiation on bicistronic simian virus 40 late mRNA. J Virol. 1987, 61 (7): 2331-2335.PubMedPubMedCentral

36.

Daniels R, Sadowicz D, Hebert DN: A very late viral protein triggers the lytic release of SV40. PLoS Pathog. 2007, 3 (7): e98-10.1371/journal.ppat.0030098.PubMedPubMedCentral

37.

Giorda KM, Raghava S, Hebert DN: The Simian virus 40 late viral protein VP4 disrupts the nuclear envelope for viral release. J Virol. 2012, 86 (6): 3180-3192. 10.1128/JVI.07047-11.PubMedPubMedCentral

38.

Khalili K, White MK, Sawa H, Nagashima K, Safak M: The agnoprotein of polyomaviruses: a multifunctional auxiliary protein. J Cell Physiol. 2005, 204 (1): 1-7. 10.1002/jcp.20266.PubMed

39.

Ng SC, Mertz JE, Sanden-Will S, Bina M: Simian virus 40 maturation in cells harboring mutants deleted in the agnogene. J Biol Chem. 1985, 260 (2): 1127-1132.PubMed

40.

Cheng J, DeCaprio JA, Fluck MM, Schaffhausen BS: Cellular transformation by simian virus 40 and murine polyoma virus T antigens. Semin Cancer Biol. 2009, 19 (4): 218-228. 10.1016/j.semcancer.2009.03.002.PubMedPubMedCentral

41.

Carter JJ, Daugherty MD, Qi X, Bheda-Malge A, Wipf GC, Robinson K, Roman A, Malik HS, Galloway DA: Identification of an overprinting gene in Merkel cell polyomavirus provides evolutionary insight into the birth of viral genes. Proc Natl Acad Sci USA. 2013, 110 (31): 12744-12749. 10.1073/pnas.1303526110.PubMedPubMedCentral

42.

Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T: Identification of novel genes coding for small expressed RNAs. Science. 2001, 294 (5543): 853-858. 10.1126/science.1064921.PubMed

43.

Kincaid RP, Sullivan CS: Virus-encoded microRNAs: an overview and a look to the future. PLoS Pathog. 2012, 8 (12): e1003018-10.1371/journal.ppat.1003018.PubMedPubMedCentral

44.

Lau NC, Lim LP, Weinstein EG, Bartel DP: An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science. 2001, 294 (5543): 858-862. 10.1126/science.1065062.PubMed

45.

Lee RC, Ambros V: An extensive class of small RNAs in Caenorhabditis elegans. Science. 2001, 294 (5543): 862-864. 10.1126/science.1065329.PubMed

46.

Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004, 116 (2): 281-297. 10.1016/S0092-8674(04)00045-5.PubMed

47.

Boss IW, Renne R: Viral miRNAs: tools for immune evasion. Curr Opin Microbiol. 2010, 13 (4): 540-545. 10.1016/j.mib.2010.05.017.PubMedPubMedCentral

48.

Slezak-Prochazka I, Durmus S, Kroesen BJ, van den Berg A: MicroRNAs, macrocontrol: regulation of miRNA processing. RNA. 2010, 16 (6): 1087-1095. 10.1261/rna.1804410.PubMedPubMedCentral

49.

Bohnsack MT, Czaplinski K, Gorlich D: Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. RNA. 2004, 10 (2): 185-191. 10.1261/rna.5167604.PubMedPubMedCentral

50.

Lund E, Guttinger S, Calado A, Dahlberg JE, Kutay U: Nuclear export of microRNA precursors. Science. 2004, 303 (5654): 95-98. 10.1126/science.1090599.PubMed

51.

Meister G, Tuschl T: Mechanisms of gene silencing by double-stranded RNA. Nature. 2004, 431 (7006): 343-349. 10.1038/nature02873.PubMed

52.

Tomari Y, Zamore PD: Perspective: machines for RNAi. Genes Dev. 2005, 19 (5): 517-529. 10.1101/gad.1284105.PubMed

53.

Yigit E, Batista PJ, Bei Y, Pang KM, Chen CC, Tolia NH, Joshua-Tor L, Mitani S, Simard MJ, Mello CC: Analysis of the C. elegans Argonaute family reveals that distinct Argonautes act sequentially during RNAi. Cell. 2006, 127 (4): 747-757. 10.1016/j.cell.2006.09.033.PubMed

54.

Carthew RW, Sontheimer EJ: Origins and mechanisms of miRNAs and siRNAs. Cell. 2009, 136 (4): 642-655. 10.1016/j.cell.2009.01.035.PubMedPubMedCentral

55.

Aleman LM, Doench J, Sharp PA: Comparison of siRNA-induced off-target RNA and protein effects. RNA. 2007, 13 (3): 385-395. 10.1261/rna.352507.PubMedPubMedCentral

56.

Djuranovic S, Nahvi A, Green R: miRNA-mediated gene silencing by translational repression followed by mRNA deadenylation and decay. Science. 2012, 336 (6078): 237-240. 10.1126/science.1215691.PubMedPubMedCentral

57.

Liu J, Carmell MA, Rivas FV, Marsden CG, Thomson JM, Song JJ, Hammond SM, Joshua-Tor L, Hannon GJ: Argonaute2 is the catalytic engine of mammalian RNAi. Science. 2004, 305 (5689): 1437-1441. 10.1126/science.1102513.PubMed

58.

Sullivan CS, Ganem D: MicroRNAs and viral infection. Mol Cell. 2005, 20 (1): 3-7. 10.1016/j.molcel.2005.09.012.PubMed

59.

Griffiths-Jones S, Grocock RJ, Van Dongen S, Bateman A, Enright AJ: miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res. 2006, 34 (Database issue): D140-D144.PubMedPubMedCentral

60.

Griffiths-Jones S, Saini HK, Van Dongen S, Enright AJ: miRBase: tools for microRNA genomics. Nucleic Acids Res. 2008, 36 (Database issue): D154-D158.PubMedPubMedCentral

61.

Pfeffer S, Zavolan M, Grasser FA, Chien M, Russo JJ, Ju J, John B, Enright AJ, Marks D, Sander C, et al: Identification of virus-encoded microRNAs. Science. 2004, 304 (5671): 734-736. 10.1126/science.1096781.PubMed

62.

Cantalupo P, Doering A, Sullivan CS, Pal A, Peden KW, Lewis AM, Pipas JM: Complete nucleotide sequence of polyomavirus SA12. J Virol. 2005, 79 (20): 13094-13104. 10.1128/JVI.79.20.13094-13104.2005.PubMedPubMedCentral

63.

Seo GJ, Fink LH, O'Hara B, Atwood WJ, Sullivan CS: Evolutionarily conserved function of a viral microRNA. J Virol. 2008, 82 (20): 9823-9828. 10.1128/JVI.01144-08.PubMedPubMedCentral

64.

Sullivan CS, Grundhoff AT, Tevethia S, Pipas JM, Ganem D: SV40-encoded microRNAs regulate viral gene expression and reduce susceptibility to cytotoxic T cells. Nature. 2005, 435 (7042): 682-686. 10.1038/nature03576.PubMed

65.

Bauman Y, Mandelboim O: MicroRNA based immunoevasion mechanism of human polyomaviruses. RNA Biol. 2011, 8 (4): 591-594. 10.4161/rna.8.4.15587.PubMed

66.

Bauman Y, Nachmani D, Vitenshtein A, Tsukerman P, Drayman N, Stern-Ginossar N, Lankry D, Gruda R, Mandelboim O: An identical miRNA of the human JC and BK polyoma viruses targets the stress-induced ligand ULBP3 to escape immune elimination. Cell Host Microbe. 2011, 9 (2): 93-102. 10.1016/j.chom.2011.01.008.PubMed

67.

Sullivan CS, Sung CK, Pack CD, Grundhoff A, Lukacher AE, Benjamin TL, Ganem D: Murine Polyomavirus encodes a microRNA that cleaves early RNA transcripts but is not essential for experimental infection. Virology. 2009, 387 (1): 157-167. 10.1016/j.virol.2009.02.017.PubMedPubMedCentral

68.

Lee S, Paulson KG, Murchison EP, Afanasiev OK, Alkan C, Leonard JH, Byrd DR, Hannon GJ, Nghiem P: Identification and validation of a novel mature microRNA encoded by the Merkel cell polyomavirus in human Merkel cell carcinomas. J Clin Virol. 2011, 52 (3): 272-275. 10.1016/j.jcv.2011.08.012.PubMedPubMedCentral

69.

Seo GJ, Chen CJ, Sullivan CS: Merkel cell polyomavirus encodes a microRNA with the ability to autoregulate viral gene expression. Virology. 2009, 383 (2): 183-187. 10.1016/j.virol.2008.11.001.PubMed

70.

Bennett MD, Woolford L, Stevens H, Van Ranst M, Oldfield T, Slaven M, O'Hara AJ, Warren KS, Nicholls PK: Genomic characterization of a novel virus found in papillomatous lesions from a southern brown bandicoot (Isoodon obesulus) in Western Australia. Virology. 2008, 376 (1): 173-182. 10.1016/j.virol.2008.03.014.PubMed

71.

Woolford L, Rector A, Van Ranst M, Ducki A, Bennett MD, Nicholls PK, Warren KS, Swan RA, Wilcox GE, O'Hara AJ: A novel virus detected in papillomas and carcinomas of the endangered western barred bandicoot (Perameles bougainville) exhibits genomic features of both the Papillomaviridae and Polyomaviridae. J Virol. 2007, 81 (24): 13280-13290. 10.1128/JVI.01662-07.PubMedPubMedCentral

72.

Chen CJ, Kincaid RP, Seo GJ, Bennett MD, Sullivan CS: Insights into Polyomaviridae microRNA function derived from study of the bandicoot papillomatosis carcinomatosis viruses. J Virol. 2011, 85 (9): 4487-4500. 10.1128/JVI.02557-10.PubMedPubMedCentral

73.

Chen CJ, Cox JE, Kincaid RP, Martinez A, Sullivan CS: Divergent microRNA Targetomes of Closely-related Circulating Strains of a Polyomavirus. J Virol. 2013, in press

74.

Acheson NH: Efficiency of processing of viral RNA during the early and late phases of productive infection by polyoma virus. J Virol. 1981, 37 (2): 628-635.PubMedPubMedCentral

75.

Hyde-DeRuyscher RP, Carmichael GG: Polyomavirus late pre-mRNA processing: DNA replication-associated changes in leader exon multiplicity suggest a role for leader-to-leader splicing in the early-late switch. J Virol. 1990, 64 (12): 5823-5832.PubMedPubMedCentral

76.

Hyde-DeRuyscher R, Carmichael GG: Polyomavirus early-late switch is not regulated at the level of transcription initiation and is associated with changes in RNA processing. Proc Natl Acad Sci USA. 1988, 85 (23): 8993-8997. 10.1073/pnas.85.23.8993.PubMedPubMedCentral

77.

Liu Z, Batt DB, Carmichael GG: Targeted nuclear antisense RNA mimics natural antisense-induced degradation of polyoma virus early RNA. Proc Natl Acad Sci USA. 1994, 91 (10): 4258-4262. 10.1073/pnas.91.10.4258.PubMedPubMedCentral

78.

Broekema NM, Imperiale MJ: miRNA regulation of BK polyomavirus replication during early infection. Proc Natl Acad Sci USA. 2013, 110 (20): 8200-8205. 10.1073/pnas.1301907110.PubMedPubMedCentral

79.

Boss IW, Renne R: Viral miRNAs and immune evasion. Biochimica et biophysica acta. 2011, 1809 (11–12): 708-714.PubMed

80.

Raulet DH: Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol. 2003, 3 (10): 781-790. 10.1038/nri1199.PubMed

81.

Zafirova B, Wensveen FM, Gulin M, Polic B: Regulation of immune cell function and differentiation by the NKG2D receptor. CMLS. 2011, 68 (21): 3519-3529. 10.1007/s00018-011-0797-0.PubMedPubMedCentral

82.

Raulet DH, Gasser S, Gowen BG, Deng W, Jung H: Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol. 2013, 31: 413-441. 10.1146/annurev-immunol-032712-095951.PubMedPubMedCentral

83.

Nachmani D, Stern-Ginossar N, Sarid R, Mandelboim O: Diverse herpesvirus microRNAs target the stress-induced immune ligand MICB to escape recognition by natural killer cells. Cell Host Microbe. 2009, 5 (4): 376-385. 10.1016/j.chom.2009.03.003.PubMed

84.

Stern-Ginossar N, Elefant N, Zimmermann A, Wolf DG, Saleh N, Biton M, Horwitz E, Prokocimer Z, Prichard M, Hahn G, et al: Host immune system gene targeting by a viral miRNA. Science. 2007, 317 (5836): 376-381. 10.1126/science.1140956.PubMedPubMedCentral

85.

You X, Zhang Z, Fan J, Cui Z, Zhang XE: Functionally orthologous viral and cellular microRNAs studied by a novel dual-fluorescent reporter system. PLoS One. 2012, 7 (4): e36157-10.1371/journal.pone.0036157.PubMedPubMedCentral

86.

Westerlaken JH, Van der Zee CE, Peters W, Wieringa B: The DMWD protein from the myotonic dystrophy (DM1) gene region is developmentally regulated and is present most prominently in synapse-dense brain areas. Brain Res. 2003, 971 (1): 116-127. 10.1016/S0006-8993(03)02430-2.PubMed

87.

Ambros V: The functions of animal microRNAs. Nature. 2004, 431 (7006): 350-355. 10.1038/nature02871.PubMed

88.

Wang Q, Li DC, Li ZF, Liu CX, Xiao YM, Zhang B, Li XD, Zhao J, Chen LP, Xing XM, et al: Upregulation of miR-27a contributes to the malignant transformation of human bronchial epithelial cells induced by SV40 small T antigen. Oncogene. 2011, 30 (36): 3875-3886. 10.1038/onc.2011.103.PubMed

89.

Gunasekharan V, Laimins LA: Human papillomaviruses modulate MicroRNA 145 expression to directly control genome amplification. J Virol. 2013, 87 (10): 6037-6043. 10.1128/JVI.00153-13.PubMedPubMedCentral

90.

Johnston SD, Yu XM, Mertz JE: The major transcriptional transactivation domain of simian virus 40 large T antigen associates nonconcurrently with multiple components of the transcriptional preinitiation complex. J Virol. 1996, 70 (2): 1191-1202.PubMedPubMedCentral

91.

Buggele WA, Horvath CM: MicroRNA profiling of Sendai virus-infected A549 cells identifies miR-203 as an interferon-inducible regulator of IFIT1/ISG56. J Virol. 2013, 87 (16): 9260-9270. 10.1128/JVI.01064-13.PubMedPubMedCentral

92.

Buggele WA, Johnson KE, Horvath CM: Influenza A virus infection of human respiratory cells induces primary microRNA expression. J Biol Chem. 2012, 287 (37): 31027-31040. 10.1074/jbc.M112.387670.PubMedPubMedCentral

93.

Zhang X, Daucher M, Armistead D, Russell R, Kottilil S: MicroRNA expression profiling in HCV-infected human hepatoma cells identifies potential anti-viral targets induced by interferon-alpha. PLoS One. 2013, 8 (2): e55733-10.1371/journal.pone.0055733.PubMedPubMedCentral

94.

Qi Y, Li Y, Zhang L, Huang J: microRNA expression profiling and bioinformatic analysis of dengue virusinfected peripheral blood mononuclear cells. Mol Med Rep. 2013, 7 (3): 791-798.PubMed

95.

Gottwein E, Mukherjee N, Sachse C, Frenzel C, Majoros WH, Chi JT, Braich R, Manoharan M, Soutschek J, Ohler U, et al: A viral microRNA functions as an orthologue of cellular miR-155. Nature. 2007, 450 (7172): 1096-1099. 10.1038/nature05992.PubMedPubMedCentral

96.

Muylkens B, Coupeau D, Dambrine G, Trapp S, Rasschaert D: Marek's disease virus microRNA designated Mdv1-pre-miR-M4 targets both cellular and viral genes. Arch Virol. 2010, 155 (11): 1823-1837. 10.1007/s00705-010-0777-y.PubMed

97.

Skalsky RL, Samols MA, Plaisance KB, Boss IW, Riva A, Lopez MC, Baker HV, Renne R: Kaposi's sarcoma-associated herpesvirus encodes an ortholog of miR-155. J Virol. 2007, 81 (23): 12836-12845. 10.1128/JVI.01804-07.PubMedPubMedCentral

98.

Zhao Y, Yao Y, Xu H, Lambeth L, Smith LP, Kgosana L, Wang X, Nair V: A functional MicroRNA-155 ortholog encoded by the oncogenic Marek's disease virus. J Virol. 2009, 83 (1): 489-492. 10.1128/JVI.01166-08.PubMedPubMedCentral

99.

Babu SG, Ponia SS, Kumar D, Saxena S: Cellular oncomiR orthologue in EBV oncogenesis. Comput Biol Med. 2011, 41 (10): 891-898. 10.1016/j.compbiomed.2011.07.007.PubMed

100.

Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, van der Meer AJ, Patick AK, Chen A, Zhou Y, et al: Treatment of HCV infection by targeting microRNA. N Engl J Med. 2013, 368 (18): 1685-1694. 10.1056/NEJMoa1209026.PubMed

101.

Moens U: Silencing viral microRNA as a novel antiviral therapy?. J Biomed Biotechnol. 2009, 2009: 419539-PubMedPubMedCentral

102.

Shimakami T, Yamane D, Jangra RK, Kempf BJ, Spaniel C, Barton DJ, Lemon SM: Stabilization of hepatitis C virus RNA by an Ago2-miR-122 complex. Proc Natl Acad Sci USA. 2012, 109 (3): 941-946. 10.1073/pnas.1112263109.PubMedPubMedCentral

103.

Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, Munk ME, Kauppinen S, Orum H: Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science. 2010, 327 (5962): 198-201. 10.1126/science.1178178.PubMedPubMedCentral

104.

Dudda JC, Salaun B, Ji Y, Palmer DC, Monnot GC, Merck E, Boudousquie C, Utzschneider DT, Escobar TM, Perret R, et al: MicroRNA-155 is required for effector CD8(+) T cell responses to virus infection and cancer. Immunity. 2013, 38 (4): 742-753. 10.1016/j.immuni.2012.12.006.PubMedPubMedCentral

105.

Lind EF, Elford AR, Ohashi PS: Micro-RNA 155 is required for optimal CD8+ T cell responses to acute viral and intracellular bacterial challenges. J Immunol. 2013, 190 (3): 1210-1216. 10.4049/jimmunol.1202700.PubMed

Title: The miRNA world of polyomaviruses
Authors: Ole Lagatie
Luc Tritsmans
Lieven J Stuyver
Publication date: 01-12-2013
Publisher: BioMed Central
Published in: Virology Journal / Issue 1/2013
Electronic ISSN: 1743-422X
DOI: https://doi.org/10.1186/1743-422X-10-268

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2013

Comparative pathogenesis of type 1 (European genotype) and type 2 (North American genotype) porcine reproductive and respiratory syndrome virus in infected boar

Bacterial artificial chromosome derived simian varicella virus is pathogenic in vivo

Dynamic interplay between CXCL levels in chronic Hepatitis C patients treated by Interferon

A novel bocavirus in canine liver

Mutation Reporter Tool: An online tool to interrogate loci of interest, with its utility demonstrated using hepatitis B virus

Comparison of polystyrene nanoparticles and UV-inactivated antigen-displaying adenovirus for vaccine delivery in mice

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials